Abstract: The present invention relates to oxalamide substituted heterocyclic compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds.
Type:
Application
Filed:
January 22, 2021
Publication date:
April 6, 2023
Applicant:
PHENEX PHARMACEUTICALS AG
Inventors:
Olaf Kinzel, Christoph Steeneck, Marta Czekanska, Sheena Pinto, Ibrahim Murathan Sektioglu, Ulrich Deuschle
Abstract: The present invention relates to compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds.
Type:
Grant
Filed:
February 1, 2018
Date of Patent:
July 5, 2022
Assignee:
PHENEX PHARMACEUTICALS AG
Inventors:
Christoph Steeneck, Ulrich Deuschle, Michael Albers, Thomas Hoffmann
Abstract: The present invention relates to isolithocholic acid (3ß-hydroxy-5ß-cholan-24-oic acid, iso-LCA) and isoallolithocholic acid (3ß-hydroxy-5?-cholan-24-oic acid) and their deuterated analogs for preventing or treating Clostridium difficile-associated disease in a mammalian subject.
Type:
Application
Filed:
August 8, 2019
Publication date:
October 21, 2021
Applicant:
PHENEX PHARMACEUTICALS AG
Inventors:
Christian Gege, Manfred Birkel, Thomas Hoffman
Abstract: The present invention relates to compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds.
Type:
Grant
Filed:
February 1, 2018
Date of Patent:
April 20, 2021
Assignee:
Phenex Pharmaceuticals AG
Inventors:
Christoph Steeneck, Ulrich Deuschle, Michael Albers, Thomas Hoffmann
Abstract: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1?), (100), (100?), (200) and (200?) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
May 29, 2013
Date of Patent:
May 28, 2019
Assignee:
Phenex Pharmaceuticals AG
Inventors:
Christian Gege, Christoph Steeneck, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann
Abstract: The invention provides modulators for the orphan nuclear receptor ROR? and methods for treating ROR? mediated diseases by administrating these novel ROR? modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of Formula (1) and the enantiomers, diastereomers, N-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
December 3, 2012
Date of Patent:
November 14, 2017
Assignee:
Phenex Pharmaceuticals AG
Inventors:
Christoph Steeneck, Olaf Kinzel, Christian Gege, Gerald Kleymann, Thomas Hoffmann
Abstract: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
May 29, 2013
Date of Patent:
October 4, 2016
Assignee:
Phenex Pharmaceuticals AG
Inventors:
Christian Gege, Olaf Kinzel, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann
Abstract: The present invention relates to compounds of formula (1): where R, A, Q and Z are defined herein, or an enantiomer, diastereomer, tautomer, solvate, prodrug or pharmaceutical acceptable salt thereof. These compounds bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.
Type:
Grant
Filed:
August 19, 2010
Date of Patent:
February 10, 2015
Assignee:
Phenex Pharmaceuticals AG
Inventors:
Claus Kremoser, Ulrich Abel, Christoph Steeneck, Olaf Kinzel
Abstract: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
April 13, 2012
Date of Patent:
February 3, 2015
Assignee:
Phenex Pharmaceuticals AG
Inventors:
Christoph Steeneck, Olaf Kinzel, Christian Gege, Gerald Kleymann, Thomas Hoffmann
Abstract: The invention provides modulators for the orphan nuclear receptor ROR? and methods for treating ROR? mediated diseases by administrating these novel ROR? modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
February 28, 2011
Date of Patent:
January 27, 2015
Assignee:
Phenex Pharmaceuticals AG
Inventors:
Olaf Kinzel, Christoph Steeneck, Gerald Kleymann, Michael Albers, Thomas Hoffmann, Claus Kremoser, Sanja Perovic-Ottstadt, Thomas Schlüter
Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
Type:
Application
Filed:
July 12, 2012
Publication date:
August 7, 2014
Applicant:
PHENEX PHARMACEUTICALS AG
Inventors:
Olaf Kinzel, Christoph Steeneck, Claus Kremoser
Abstract: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.
Type:
Application
Filed:
April 13, 2012
Publication date:
May 22, 2014
Applicant:
PHENEX PHARMACEUTICALS AG
Inventors:
Christoph Steeneck, Olaf Kinzel, Christian Gege, Gerald Kleymann, Thomas Hoffmann
Abstract: The invention provides modulators for the orphan nuclear receptor ROR? and methods for treating ROR? mediated diseases by administrating these novel ROR? modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.
Type:
Application
Filed:
February 28, 2011
Publication date:
February 28, 2013
Applicant:
PHENEX PHARMACEUTICALS AG
Inventors:
Olaf Kinzel, Christoph Steeneck, Gerald Klaymann, Michael Albers, Thomas Hoffman, Claus Kremoser, Sanja Perovic-Ottstadt, Thomas Schlüter
Abstract: The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.
Type:
Application
Filed:
August 19, 2010
Publication date:
September 13, 2012
Applicant:
PHENEX PHARMACEUTICALS AG
Inventors:
Claus Kremoser, Ulrich Abel, Christoph Steeneck, Olaf Kinzel
Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.
Type:
Grant
Filed:
August 29, 2007
Date of Patent:
June 5, 2012
Assignee:
Phenex Pharmaceuticals AG
Inventors:
Claus Kremoser, Ulrich Deuschle, Ulrich Abel, Andreas Schulz
Abstract: The invention relates to modulators for the orphan nuclear receptor RORgamma and methods for identification and screening of novel modulators for RORgamma activity as well as methods for treating RORgamma mediated diseases with novel RORgamma modulators identified by such methods.
Type:
Application
Filed:
October 28, 2009
Publication date:
October 27, 2011
Applicant:
PHENEX PHARMACEUTICALS AG
Inventors:
Ulrich Deuschle, Ulrich Abel, Claus Kremoser, Thomas Schlueter, Thomas Hoffmann, Sanja Perovic-Ottstadt
Abstract: The present invention relates to compounds which bind to the NRI H4 receptor (FXR) and act as agonists or partial agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.
Type:
Application
Filed:
August 29, 2007
Publication date:
August 19, 2010
Applicant:
PHENEX PHARMACEUTICALS AG
Inventors:
Claus Kremoser, Ulrich Deuschle, Ulrich Abel, Andreas Schulz
Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.
Type:
Application
Filed:
August 29, 2007
Publication date:
July 22, 2010
Applicant:
PHENEX PHARMACEUTICALS AG
Inventors:
Claus Kremoser, Ulrich Deuschle, Ulrich Abel, Andreas Schulz
Abstract: The invention provides compounds according to the general formula (1) which bind to the NR1H4 receptor and act as agonists, antagonists or mixed agonists/antagonists of the NR1H4 receptor. The invention further provides methods of treating diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.
Type:
Grant
Filed:
August 13, 2002
Date of Patent:
August 29, 2006
Assignee:
Phenex Pharmaceuticals AG
Inventors:
Ulrike Bauer, Zach Cheruvallath, Ulrich Deuschle, Elena Dneprovskaia, Tim Gahman, Kristina Giegrich, Ronnie Hanecak, Normand Hébert, John Kiely, Ingo Kober, Manfred Kögl, Harald Kranz, Claus Kremoser, Matthew Lee, Kerstin Otte, Carlton Sage, Manish Sud
Abstract: The present invention relates to compounds according to the general formula (I) which bind to the nuclear receptor, NR1H4, and act as agonists and antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds.
Type:
Grant
Filed:
July 1, 2002
Date of Patent:
April 25, 2006
Assignee:
Phenex Pharmaceuticals AG
Inventors:
Ulrike Bauer, Zach Cheruvallath, Ulrich Deuschle, Elena Dneprovskaia, Tim Gahman, Kristina Giegrich, Ronnie Hanecak, Normand Hébert, John Kiely, Ingo Kober, Manfred Kögl, Harald Kranz, Claus Kremoser, Matthew Lee, Kerstin Otte, Carlton Sage, Manish Sud